Testosterone, gonadotropins, and genetic polymorphisms in men with Alzheimer's disease

Hormones, Cognition and Dementia: State of The Art and Emergent Therapeutic Strategies

Volumn , Issue , 2009, Pages 171-178

  Hogervorst, Eef ^a   Bandelow, Stephan ^a   Lehmann, Donald ^b  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927044774     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511635700.019     Document Type: Chapter

References (45)

1. Ahlbom E, Prins GS, Ceccatelli S. Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Res. 2001; 892:255-62.
2. Hammond J, Le Q, Goodyer C, et al. Testosterone mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem. 2001; 77:1319-26.
3. Pike CJ. Testosterone attenuates b-amyloid toxicity in cultured hippocampal neurons. Brain Res. 2001; 919:160-5.
4. Lessov-Schlaggar CN, Reed T, Swan GE, et al. Association of sex steroid hormones with brain morphology and cognition in healthy elderly men. Neurology. 2005; 65(10):1591-6.
5. Hogervorst E, Williams J, Budge M, et al. Serum total testosterone is lower in men with Alzheimer’s disease. Neuroendocrinology Lett. 2001; 22(3):163-8.
6. Roth M, Huppert FA, Tym E, Mountjoy C. CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly. Cambridge: Cambridge University Press, 1988.
7. Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer’s disease. Exp Gerontol. 2004; 39(11/12): 1633-9.
8. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004; 62(2):188-93.
9. Paoletti AM, Congia S, Lello S, et al. Low androgenization index in elderly women and elderly men with Alzheimer’s disease. Neurology. 2004; 62(2):301-3.
10. Svartberg M, Midtby M, Bonaa KH, et al. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. EurJEndo. 2003; 149(2):145-52.
11. Hoskin EK, Tang MX, Manly JJ, Mayeux R. Elevated sex-hormone binding globulin in elderly women with Alzheimer’s disease. Neurobiol Aging. 2004; 25(2):141-7.
12. Brenta G, Schnitman M, Gurfinkiel M, et al. Variations of sex hormone-binding globulin in thyroid dysfunction. Thyroid. 1999; 9(3):273-7.
13. Skjoldebrand-Sparre L, Kollind M, Carlstrom K. Ovarian ultrasound and ovarian and adrenal hormones before and after treatment for hyperthyroidism. Gynecol Obstet Invest. 2002; 54(1):50-5.
14. Zahringer S, Tomova A, von Werder K, et al. The influence of hyperthyroidism on the hypothalamic- pituitary-gonadal axis. Exp Clin Endocrinol Diabetes. 2002; 108(4):282-9.
15. van Osch LA, Hogervorst E, Combrinck M, Smith AD. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology. 2004; 62(11):1967-71.
16. Demers LM, Spencer CA. NACB, Biochemistry TNAoC, Laboratory Medicine Practice Guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Available at http://www.nacb.org/lmpg/thyroid_LMPG_PDF.stm.
17. Kalmijn S, Mehta KM, Pols HAP, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol. 2000; 53:733-7.
18. Wahlin A, Wahlin TB., Small BJ, Backman L. Influences of thyroid stimulating hormone on cognitive functioning in very old age. J Gerontol Ser B Psychol Sci. 1998; 53(4): P234-P239.
19. Wahlin A, Bunce D, Wahlin TB. Longitudinal evidence of the impact of normal thyroid stimulating hormone variations on cognitive functioning in very old age. Psychoneuroendocrinology. 2005; 30(7):625-37.
20. Hogervorst E, Matthews F, Huppert FA, Brayne C. Thyroid function and cognitive decline in the MRC Cognitive Function & Ageing Study. Psychoneuroendocrinology. 2008; 33(7):1013-22.
21. Tsitouras PD, Bulat T. The aging male reproductive system. Endocrinol Metab Clin North Am. 1995; 24:297-315.
22. Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease ? J Neuroendocrinol. 2000; 12(4):351-4.
23. Short RA, Bowen RL, O’Brien PC, Graff Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001; 76(9):906-9
24. Schrijnemaeckers AMC, De Jager CA, Hogervorst E, Budge MM. Cases with Mild Cognitive Impairment and Alzheimer’s disease fail to benefit from repeated exposure to episodic memory tests as compared with controls. J Clin Exp Neuropsychol. 2006; 28(3):438-55.
25. De Jager CA, Hogervorst E, Combrinck M, Budge MM. Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer’s disease. Psychol Med. 2003; 33(6):1039-50.
26. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta- amyloid, memory and depression in men. Psychoneuroendocrinology. 2004; 29(8):1071-81.
27. Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 2004; 93(7):975-9.
28. Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol. 2003; 170(5):1808-11.
29. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res. 2004; 10(22):7575-82.
30. Grigorova M, Sherwin BB, Tulandi T. Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology. 2006; 31 (8):935-47.
31. Sherwin BB, Tulandi T. “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab. 1996; 81(7):2545-9.
32. Newton C, Slota D, Yuzpe AA, Tummon IS. Memory complaints associated with the use of gonadotropinreleasing hormone agonists: a preliminary study. Fertil Steril. 1996; 65(6):1253-5.
33. Varney NR, Syrop C, Kubu CS, et al. Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism. J Assist Reprod Genet. 1993; 10(1):53-7.
34. Cherrier MM, Matsumoto AM, Amory JK, et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology. 2005; 64(2):290-6.
35. Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004; 13(1):94-101.
36. Iivonen S, Corder E, Lehtovirta M, et al. Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease. Neurology. 2004; 62(7): 1170-6.
37. Rosario ER, Chang L, Stanczyk FZ, Pike CJ. Age- related testosterone depletion and the development of Alzheimer disease. JAMA. 2004; 292(12):1431-2.
38. Hogervorst E, Lehmann DJ, Warden DR, McBroom J, Smith AD. Apolipoprotein E epsilon4 and testosterone interact in the risk of Alzheimer’s disease in men. Int J Geriatr Psychiatry. 2002; 17(10):938-40.
39. Burkhardt MS, Foster JK, Clarnette RM, et al. Interaction between testosterone and apolipoprotein E epsilon4 status on cognition in healthy older men. J Clin Endocrinol Metab. 2006; 91(3):1168-72.
40. Raber J, Bongers G, Le Fevour A, Buttini M, Mucke L. Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci. 2002; 22(12):5204-9.
41. Yaffe K, Edwards ER, Lui LY, et al. Androgen receptor CAG repeat polymorphism is associated with cognitive function in older men. Biol Psychiatry. 2003; 54(9):943-6.
42. Lehmann DJ, Butler HT, Warden DR, et al. Association of the androgen receptor CAG repeat polymorphism with Alzheimer disease in men. Neurosci Lett. 2003; 340(2):87-90.
43. Lehmann DJ, Hogervorst E, Warden DR, et al. The androgen receptor CAG repeat and serum testosterone in the risk of Alzheimer’s disease in men. J Neurol Neurosurg Psychiatry. 2004; 75(1):163-4.
44. Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol. 2000; 25(1):85-96.
45. Krithivas K, Yurgalevitch SM, Mohr BA, et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol. 1999; 162(1):137-42.